Aggregated price index with volume information
- Genetic Testing Firms stocks down 1.6% on average while median return down 1.5% in a day
- Genetic Testing Firms stocks down 1.8% on average while median return down 2.1% in a week
- Genetic Testing Firms stocks down 14.3% on average while median return down 17.6% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are
- 1M losers are : Losers for past month are $NEOG -19.6%, $FLGT -20.3%, $CODX -20.9%, $NTRA -25.1%
- 1W winners are : Winners for past week are $CODX 1.0%
- 1W losers are : Losers for past week are $FLGT -2.1%, $NEOG -2.7%, $NTRA -3.4%, $MYGN -3.4%
Index correlation analysis
Correlation for the past month is 24.4%, for the past 3 months is 18.9%
In the past month for a 5 days rolling window, the highest corrrelation is 57.7%, the lowest correlation is 5.3%, the latest correlation is 20.5%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 62.8% between NTRA and VCYT
The lowest correlation is -19.2% between CODX and NEOG
Unpacking the Risks and Rewards of Investing in Myriad Genetics (MYGN)
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2023 before the market opens on Thursday, October 26, 2023. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
A new national survey from Myriad Genetics Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed that breast density and family health history are two misunderstood breast cancer risk factors.
SOUTH SAN FRANCISCO, Calif., September 28, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at the 2023 American Thyroid Association (ATA) Annual Meeting demonstrate the type of novel molecular insights for thyroid nodules and cancer that are enabled by analysis with the Afirma Genomic Sequencing Classifier (GSC). Presented by clinical researchers in three posters, the findings are based on Afirma whole-transcriptome RNA sequencing data and reveal novel molecular profi
Investors are increasingly optimistic about Labcorp (LH) due to its progress in hospital partnerships.
SOUTH SAN FRANCISCO, Calif., September 28, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego.
SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey revealing breast density and family health history are two misunderstood breast cancer risk factors. The Myriad Genetics Cancer Risk Survey found that nearly half (48%) of the women surveyed do not know what breast density is, and 50% are unsure if breast density has anything to do with breast cancer risk. Wo
Graves Gilbert, a multispecialty clinic comprised of more than 200 providers representing over 30 medical specialties in Bowling Green, Kentucky, and surrounding counties, is proud to announce a collaboration with Circuit Clinical, an integrated research organization, to bring clinical trials to patients in South Central Kentucky. The partnership supports broader efforts to bring clinical research to community settings, advance medical treatments, and improve equitable healthcare for diverse and
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be sponsoring and participating in the Utah Health Care Association/Utah Center for Assisted Living Convention (UHCA/UCAL) & Expo at the Mountain America Expo Center in Sandy, Utah on September 27-28, 2023.
Within the biosecurity portfolio, Neogen (NEOG) continues to record solid growth in cleaners, disinfectants and rodenticides.